141 related articles for article (PubMed ID: 11310595)
21. 2-(1-Naphthyloxy)ethylamines with enhanced affinity for human 5-HT1D beta (h5-HT1B) serotonin receptors.
Ismaiel AM; Dukat M; Law H; Kamboj R; Fan E; Lee DK; Mazzocco L; Buekschkens D; Teitler M; Pierson ME; Glennon RA
J Med Chem; 1997 Dec; 40(26):4415-9. PubMed ID: 9435911
[TBL] [Abstract][Full Text] [Related]
22. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.
Longmore J; Maguire JJ; MacLeod A; Street L; Schofield WN; Hill RG
Br J Clin Pharmacol; 2000 Feb; 49(2):126-31. PubMed ID: 10671906
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Napier C; Stewart M; Melrose H; Hopkins B; McHarg A; Wallis R
Eur J Pharmacol; 1999 Mar; 368(2-3):259-68. PubMed ID: 10193663
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions.
Marcoli M; Maura G; Munari C; Ruelle A; Raiteri M
Br J Pharmacol; 1999 Feb; 126(3):607-12. PubMed ID: 10188970
[TBL] [Abstract][Full Text] [Related]
26. 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
Prisinzano T; Dukat M; Law H; Slassi A; MacLean N; DeLannoy I; Glennon RA
Bioorg Med Chem Lett; 2004 Sep; 14(18):4697-9. PubMed ID: 15324890
[TBL] [Abstract][Full Text] [Related]
27. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
Glennon RA; Hong SS; Bondarev M; Law H; Dukat M; Rakhi S; Power P; Fan E; Kinneau D; Kamboj R; Teitler M; Herrick-Davis K; Smith C
J Med Chem; 1996 Jan; 39(1):314-22. PubMed ID: 8568822
[TBL] [Abstract][Full Text] [Related]
28. 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
Russell MG; Matassa VG; Pengilley RR; van Niel MB; Sohal B; Watt AP; Hitzel L; Beer MS; Stanton JA; Broughton HB; Castro JL
J Med Chem; 1999 Dec; 42(24):4981-5001. PubMed ID: 10585208
[TBL] [Abstract][Full Text] [Related]
29. Importance of h5-HT1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely-moving guinea-pig.
Roberts C; Price GW; Gaster L; Jones BJ; Middlemiss DN; Routledge C
Neuropharmacology; 1997; 36(4-5):549-57. PubMed ID: 9225280
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
31. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
Selkirk JV; Scott C; Ho M; Burton MJ; Watson J; Gaster LM; Collin L; Jones BJ; Middlemiss DN; Price GW
Br J Pharmacol; 1998 Sep; 125(1):202-8. PubMed ID: 9776361
[TBL] [Abstract][Full Text] [Related]
32. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
33. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
[TBL] [Abstract][Full Text] [Related]
34. Cloning of serotonin 5-HT(1) receptor subtypes from the chimpanzee, gorilla and Rhesus monkey and their agonist-induced guanosine 5'gamma(35)S triphosphate binding.
Alberts GL; Pregenzer JF; Im WB; Slightom JL
Neurosci Lett; 2000 Feb; 280(3):223-7. PubMed ID: 10675801
[TBL] [Abstract][Full Text] [Related]
35. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
[TBL] [Abstract][Full Text] [Related]
36. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
Goadsby PJ; Knight Y
Br J Pharmacol; 1997 Nov; 122(5):918-22. PubMed ID: 9384509
[TBL] [Abstract][Full Text] [Related]
38. Serotonin receptor ligands: treatments of acute migraine and cluster headache.
Goadsby PJ
Handb Exp Pharmacol; 2007; (177):129-43. PubMed ID: 17087122
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: changes in ligand binding, G-protein coupling and second messenger formation.
Kiel S; Brüss M; Bönisch H; Göthert M
Pharmacogenetics; 2000 Oct; 10(7):655-66. PubMed ID: 11037806
[TBL] [Abstract][Full Text] [Related]
40. The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons.
Donaldson C; Boers PM; Hoskin KL; Zagami AS; Lambert GA
Neuropharmacology; 2002 Mar; 42(3):374-85. PubMed ID: 11897116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
